Ahmed Atteeque, Kanwal Romaisa, Channar Pervaiz Ali, Alshahrani Mohammad Y, Saeed Aamer, Ejaz Syeda Abida, Attaullah Hafiz Muhammad, Bibi Rifhat, Li Chen
Department of Chemistry, Quaid-i-Azam University, Islamabad, 45321, Pakistan.
Sulaiman Bin Abdullah Aba Al-Khail-Centre for Interdisciplinary Research in Basic Sciences (SA-CIRBS), International Islamic University, Islamabad, 44000, Pakistan.
Sci Rep. 2025 Jul 1;15(1):22032. doi: 10.1038/s41598-025-03115-3.
A new series of thiazolyl-coumarin-drug conjugates were synthesized through the reaction of 3-bromoacetylcoumarin and N-substituted and N, N-di-substituted thioureas. The synthesized compounds were characterized byH-NMR,C-NMR and FTIR spectroscopy and thoroughly analyzed through in-vitro and in-silico studies. Among these, derivatives 8b and 8d demonstrated significant inhibitory effects during in vitro analysis. Compound 8b exhibited a notable inhibition potential exhibiting IC = 0.32 ± 0.04 µM against CAIX, while compound 8d showed a potent inhibitory effect with IC = 0.38 ± 0.02 µM and 0.61 ± 0.05 µM against CAII and CAXII isozymes, respectively. Surpassing its standard inhibitor acetazolamide. Electronic characteristics of all synthesized hybrid compounds were accessed via density functional theory calculations (DFTs). Furthermore, the results were validated via molecular docking studies. Drug likeness properties were predicted at the end via ADMET analysis, to support the investigations. The comprehensive experimental and computational analyses supported the conclusion that the synthesized hybrid compounds possess the potential to act as inhibitors against different types of carbonic anhydrases. Overall, this study will open new avenues for the development of dual inhibitors of CAII and CAXII, displaying versatile therapeutic applications.
通过3-溴乙酰香豆素与N-取代和N,N-二取代硫脲的反应合成了一系列新的噻唑基-香豆素-药物缀合物。通过1H-NMR、13C-NMR和FTIR光谱对合成的化合物进行了表征,并通过体外和计算机模拟研究进行了全面分析。其中,衍生物8b和8d在体外分析中表现出显著的抑制作用。化合物8b对CAIX表现出显著的抑制潜力,IC50 = 0.32 ± 0.04 μM,而化合物8d对CAII和CAXII同工酶分别表现出有效的抑制作用,IC50分别为0.38 ± 0.02 μM和0.61 ± 0.05 μM,超过了其标准抑制剂乙酰唑胺。通过密度泛函理论计算(DFT)获得了所有合成杂化化合物的电子特性。此外,通过分子对接研究验证了结果。最后通过ADMET分析预测了药物相似性性质,以支持研究。全面的实验和计算分析支持了以下结论:合成的杂化化合物具有作为不同类型碳酸酐酶抑制剂的潜力。总体而言,本研究将为开发CAII和CAXII双重抑制剂开辟新途径,显示出广泛的治疗应用。